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Background. To report on the use and feasibility of a multimodality approach using concomitant radiotherapy and chemotherapy
in patients with high-risk nonmelanoma skin carcinoma (NMSC) of the head and neck. Methods. Records of patients with NMSC
of the head and neck who received concomitant CRT at the University of North Carolina between 2001 and 2007 were reviewed.
Results. Fifteen identiﬁed patients had at least one of the following high-risk factors: T4 disease (93%), unresectability (60%),
regional nodal involvement (40%), and/or recurrence (47%). Ten patients were treated in the deﬁnitive setting and ﬁve in the
postoperative setting. Platinum based chemotherapy was given in 14 (93%) patients. Ten of ﬁfteen (67%) patients completed all
planned chemotherapy treatments, and thirteen patients (87%) completed at least 80% of planned chemotherapy. Mild radiation
dermatitis occurred in all patients and reached grade 3 in 13% of patients. No patients experienced grade 4 or 5 toxicity. With a
median followup of 31 months in surviving patients, the 2-year actuarial locoregional control and relapse-free survival were 79%
and 49%, respectively. Conclusions. Deﬁnitive or postoperative chemoradiotherapy for patients with locally advanced or regionally
metastasized NMSC of the head and neck appears feasible with acceptable toxicities and favorable locoregional control.
1.Introduction
Nonmelanoma skin carcinoma (NMSC) is the most com-
mon malignancy worldwide with an incidence of over 1.3
million in the United States, making it an important global
public health issue [1]. NMSCs arise in anatomic areas
subject to frequent sun exposure, most commonly in the
head and neck [2]. When diagnosed at an early stage, local-
ized squamous and basal cell carcinomas of the skin have
high cure rates of greater than 90% with local treatments
such as surgical excision, Mohs’ chemosurgery, electrocau-
tery, and radiotherapy (RT) [3, 4].
However, subsets of these cancers can be biologically and
clinically aggressive with a greater propensity for local, re-
gionalnodal, and,toalesserextent,distantmetastaticspread
[5]. These “high-risk” NMSCs have been reported to be as-
sociated with certain adverse prognostic features, including
large tumor size, high grade, deep invasion, regional nodal
involvement, recurrent disease, perineural invasion, and im-
munosuppression [6–8].
The optimal management of these high-risk tumors is
unclear due to the paucity of data. Despite aggressive treat-
ment with surgery and/or RT, locoregional failures represent
theﬁrstsiteofrecurrenceinthemajority(70–80%)[9,10]of2 International Journal of Surgical Oncology
thesepatientsandareassociatedwithconsiderablemorbidity
and disease-related mortality [3, 11–14]. Optimizing locore-
gional control, therefore, may signiﬁcantly improve long-
term clinical outcomes. One proposed method of intensi-
fying locoregional treatment is through a multidisciplinary
approach of integrating surgery, RT, and chemotherapy in
various combinations.
There has been increasing interest in the use of chem-
otherapy for NMSCs [15]. The addition of chemotherapy
for tumor radiosensitization to increase locoregional tumor
control is an approach that could potentially improve out-
comes in these high-risk patients. The superiority of chem-
oradiotherapy (CRT) over RT alone has been established
for squamous cell carcinomas in many other tumor sites,
including mucosal head and neck [16–19], esophageal [20],
cervical [21–23], and anal carcinomas [24, 25]. However, the
role of adding chemotherapy to RT in high-risk NMSCs has
largely been unexplored with evidence limited to isolated
case reports [26, 27].
The feasibility and toxicities of combining a systemic ra-
diosensitizing agent with RT in this group of patients are
unknown, particularly because these patients possess patient
and tumor characteristics, such as older age and superﬁcial
tumor location, which may confer diﬀerent toxicities com-
pared to those experienced in patients treated for mucosal
tumors of the head and neck. We report our institutional
experience on the feasibility, toxicity, and outcomes of treat-
ing high-risk NMSCs of the head and neck with concomitant
CRT.
2. Patientsand Methods
Patients with NMSCs of the head and neck treated with
concomitant CRT from 2001 to 2007 were identiﬁed by re-
viewing the head and neck database at the University of
North Carolina Hospitals (Lineberger Comprehensive Can-
cer Center, Chapel Hill, NC, USA). Patients with histologies
other than squamous or basal cell carcinoma and NMSC
of the lip were excluded, since these patients were treated
primarily with surgery alone at our institution. Patients were
evaluatedbyamultimodalityteamconsistingoftheheadand
neck surgeon, medical oncologist, and radiation oncologist.
For comparison, records of patients with NMSC of the head
and neck treated with RT alone were also evaluated from
1990 to 2007. To select patients with high-risk features, pa-
tients treated only for cosmetic purposes or personal prefer-
ence were excluded from the RT-alone patient group.
Clinical and histopathologic data were gathered on pa-
tient characteristics, treatment delivered, acute and late toxi-
cities, and treatment outcomes. Patients were staged accord-
ing to the AJCC cancer staging guidelines for carcinoma of
the skin, excluding eyelid, vulva, and penis [28]. Toxicities
were scored according to the Common Terminology Criteria
for Adverse Events (CTCAE), version 3.0, for chemotherapy
and to the Radiation Therapy Oncology Group (RTOG)
criteria for RT. Locoregional failure was deﬁned as the reap-
pearance of tumor in the original tumor bed or development
of cervical or intraparotid node metastases after treatment.
Survivaloutcomesweremeasuredfromthetimeoftreatment
start. This study was approved by the University of North
Carolina Biomedical Institutional Review Board.
Diﬀerences in means were tested by the Welch two-
sample t-test. Rates of locoregional control were estimated
according to the method of cumulative incidence [29], and
diﬀerences were assessed by the Gray’s test [30]. Rates of
relapse-free survival and overall survival were estimated
according to the Kaplan-Meier method [31], and diﬀerences
between groups were assessed by log-rank statistic [32].
Hazard ratios were calculated using the Cox proportional
hazard method. Diﬀerences in proportions were assessed by
the 2-sample test for equality of proportions with continuity
correction. All P values reported are for 2-sided tests. The
statistical software package R 2.9.1 was used for all statistical
testing except for rendering of the Kaplan-Meier plots which
were performed in GraphPad Prism [33].
3. Results
3.1. Patient Characteristics. Fifteen patients with NMSC of
the head and neck treated with concomitant CRT and
30 patients treated with RT-alone were identiﬁed. Median
followup in surviving patients was 31 months (range, 9–
71 months) for CRT patients and 35 months (range, 2–223
months) for RT-alone patients. Nearly all patients (89%)
were male and Caucasian (98%) (Table 1). The median age
(66 years) in these patients is expected given the typical
age at presentation for NMSCs. The majority of patients in
both groups had squamous cell histology (73% CRT, 63%
RT). Treatment was considered curative in 29 patients and
palliativeforaggressivelocalcontrolin1patientforRTalone
patients. All patients treated with CRT were treated with
curative intent. No patient had immunosuppression.
Patients treated with CRT had at least one of the fol-
lowing high-risk factors: T4 disease (93%), unresectability
(60%), regional nodal involvement (40%), and/or recur-
rence (47%). Overall, patients in the CRT group possessed
more high-risk tumor features compared to RT patients:
large tumor size (T stage), nodal involvement, unresectable
tumors, bone invasion, soft tissue invasion, extracapsular
extension, multiple recurrences, and high-grade status. Of
these adverse factors, T stage, unresectability, and bone in-
vasion were statistically diﬀerent. All patients except 1 in the
CRT group had T4 disease (93%) compared to 47% in the
RT group. In parallel with the diﬀerences in resectability and
T stage between the two groups, patients treated with CRT
tended to be treated in the deﬁnitive treatment setting (67%)
compared to the postoperative setting (50%) in RT-treated
patients. An example of a patient treated with CRT is shown
in Figure 1.
3.2. Treatment Delivered. RT was delivered daily for 5 days
a week. The median dose of radiation to gross disease was
7 0 G y( r a n g e :5 8t o7 5 G y )i n1 . 8t o2 G yf r a c t i o n s .O n e
patient was planned to receive 70Gy, but only received
58Gyduetotreatmenttoxicity.Forsubclinical(microscopic)
disease, the median radiation dose was 50Gy (range: 46 to
61Gy) in 1.8 to 2.0Gy fractions. Photons only were delivered
in 3 patients and a combination of photons and electrons inInternational Journal of Surgical Oncology 3
Table 1: Patient and primary tumor characteristics.
No. (%)
CRT RT
Total number 15 30
Mean age (yrs) 65 (range, 47–84) 66 (range, 48–89)
Gender
Male 14 26
Female 1 4
Histology
Squamous cell 11 19
Basal cell 4 11
Location
Cheek 3 2
Ear 2 5
Eye 1 4
Forehead 2 4
Neck 1 3
Nose 2 1
Preauricular 2 7
Scalp 2 4
Ts t a g e
T1 0 1
T2 0 4
T3 1 2
T4 14 14
Tx 0 9
Ns t a g e
N0 9 22
N1 6 8
Presentation
Primary 8 11
Recurrent 7 19
Primary treatment
Deﬁnitive 10 10
Postoperative 5 20
Tumor features
Unresectable 9 (60) 7 (23)
Bone invasion 8 (53) 6 (20)
Nerve invasion 3 (20) 8 (27)
Soft tissue invasion 7 (47) 8 (27)
Positive margins 2 (40)∗ 9 (45)∗
ECE 2 (13) 2 (7)
Multiple recurrence 3 (20) 1 (3)
High grade† 9 (90)†† 8 (62)††
∗Postoperative patients, †moderately to poorly diﬀerentiated, ††available
tumor grade. CRT, chemoradiotherapy; RT, radiotherapy alone; ECE, ex-
tracapsular extension.
12 patients. All patients were treated using CT-based three-
dimensional treatment planning. Four patients received
intensity-modulated radiation therapy (IMRT), primarily
for parotid gland sparing. Tissue-equivalent bolus was used
in 8 patients to increase the skin surface dose to the tumor.
Figure 1: Patient treated with concomitant chemoradiotherapy:
60-year-old white female with an unresectable locally advanced T4
basal carcinoma of the right forehead involving the frontal sinus,
lateral orbit, extraocular muscles, and eyelid. She received 70Gy of
radiation given concomitantly with weekly cisplatin 30mg/m2.
In each case, the decision to oﬀer chemotherapy in com-
bination with RT was made at the recommendation of the
multidisciplinary head and neck tumor board and in agree-
ment between the treating medical oncologist and radiation
oncologist based on overall patient risk. The chemotherapy
regimens employed were at the discretion of the treating
medical oncologist. A platinum-based regimen was given
concomitantly with RT in 14 of 15 (93%) patients. Weekly
cisplatin (20–30mg/m2 in 8 patients) or weekly carboplatin
(AUC 2 in 2 patients) was used as the sole radiosensitizer in
10 patients, while 3 patients received two agents concomi-
tantly(carboplatinand5-FU,cisplatinand5-FU,carboplatin
and paclitaxel). One patient received oral therapy with
capecitabine, while another received cisplatin 100mg/m2
delivered every 3 weeks.
3.3. Treatment Tolerance and Toxicity. In CRT patients,
chemotherapy was well tolerated overall with 10 of 15 (67%)
patients completing all planned treatments. Thirteen of
ﬁfteen (87%) patients completed at least 80% of planned
chemotherapy and fourteen of ﬁfteen (93%) completed all
planned courses of radiation. Two patients had hematologic
toxicity that precluded one cycle of therapy (one patient had
a platelet count of 89,000 and one patient had a WBC count
of1.7withANC1.0),whileonepatientmissedonetreatment
due to nonadherence. The remaining 2 patients missed treat-
ment because of grade 3 mucositis or delirium. Every patient
who did not complete all treatments (n = 5) received weekly
carboplatin or cisplatin.
During concomitant chemotherapy, no patient experi-
enced grade 4 or 5 acute toxicity (Table 2). The most com-
mon acute toxicity was radiation dermatitis, which occurred
in all 15 patients and was mild (grade 1 or 2) in nearly all
patients (87%). Only 2 patients (13%) experienced grade
3 dermatitis that required radiation treatment breaks of
2 and 6 days, respectively. In one patient, the cheek and
maxillary sinus was treated with mixed photons and elec-
trons concomitantly. The other patient was treated with4 International Journal of Surgical Oncology
Table 2: Overall toxicity in chemoradiotherapy patients.
Toxicity Grade Total No.
123
Dermatitis 3 10 2 15
Mucositis 0 4 1 5
Conjunctivitis 2 1 0 3
Keratitis 1 0 2 3
Xerostomia 3 1 0 4
Altered mental status 0 0 1 1
Hearing loss 0 1 0 1
Tinnitus 0 1 0 1
Nausea 4 1 0 5
Vomiting 1 1 0 2
Dysphagia 1 0 0 1
Odynophagia 2 0 0 2
Dysgeusia 1 3 0 4
Anorexia 0 2 0 2
Weight loss 0 4 0 4
Fatigue 5 2 0 7
Creatinine elevation 1 0 0 1
Hypocalcemia 1 1 0 2
Hypomagnesemia 4 1 0 5
Hyponatremia 1 0 0 1
Anemia 3 0 0 3
Leukopenia 1 2 2 5
Lymphopenia 2 2 4 8
Neutropenia 1 3 0 4
Thrombocytopenia 3 0 0 3
electrons to the primary forehead site and photons to the
neck via IMRT. Tissue-equivalent bolus and concomitant
weekly carboplatin was used in both of these patients. Six of
the other eight patients in which bolus was used developed
grade 2 dermatitis.
Mucositis occurred in 5 patients (33%), reaching grade
3 in only 1 patient (7%). This patient was treated with
extensive radiation ﬁelds encompassing nearly the entirety of
his left face, including the orbit and maxillary sinus, along
with weekly cisplatin. Grade 3 keratitis occurred in 2 patients
who had tumor directly involving or adjacent to the orbits,
which unavoidably received the full prescribed dose (70Gy
and 50.4Gy, resp.). One patient, aged 84, experienced acute
altered mental status changes that required hospitalization
forgrade3delirium.HistreatmentwithconcomitantRTand
weekly carboplatin was stopped early because of this toxicity.
Grade 3 leukopenia and lymphopenia were observed in
2 and 4 patients, respectively. One patient had a grade 1
creatinine elevation prompting change in regimen from cis-
platin 30mg/m2 to carboplatin AUC thrice weekly. Nausea,
vomiting, and fatigue were limited to grade 1 or 2 toxicities,
and no patient had grade 3 or 4 electrolyte abnormalities.
Serious late toxicities were rare, occurring in only 2
patients. One patient developed grade 3 osteoradionecrosis
of the temporal bone, and another patient experienced
CRT
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Figure 2: Rates of locoregional control in chemoradiotherapy
(CRT) and radiotherapy alone (RT) treated patients.
grade 3 chronic otitis media with associated hearing loss.
These toxicities were expected because these normal tissue
structureswere within the high-risk radiation target volumes
and received the full prescribed dose.
3.4. Treatment Outcomes. The estimated 2-year locoregional
control rates were 79% for CRT and 69% for RT patients
(Figure 2).Themediantimetorecurrencewas7months,and
greater than 85% of the failures occurred within 24 months
of treatment. The estimated 2-year relapse-free survival rates
for the CRT and RT groups were 49% and 60%, respectively
(Figure 3). The estimated 2-year overall survival rates were
65%(CRT)and86%(RT).Ofthosewhodied,5patientsdied
with recurrent disease, and 2 patients died without evidence
of disease.
On univariate analysis for relapse-free survival on all
patients, there was a trend towards decreased relapse-free
survival for soft tissue and nerve invasion, nodal involve-
ment, and positive margins, but these were not statistically
signiﬁcant (Table 3). The only statistically signiﬁcant factor
in the univariate analysis was bone invasion (HR, 5.25; P<
0.01).
On multivariate analysis, both bone invasion (HR, 9.43;
CI, 2.8–32; P<0.01) and nodal involvement (HR, 2.60;
CI, 1.3–5.1; P = 0.01) were highly statistically signiﬁ-
cantly associated with worse outcome. As previously noted,
bone invasion was associated with the decision to add
chemotherapy to RT. Therefore, we investigated the potential
confounding on estimates of treatment eﬀect by bone
invasion status. When controlling for bone invasion and
nodal involvement by Cox proportional hazards modeling,
we detected a trend toward clinical beneﬁt of combined
modality CRT over RT alone for relapse-free survival (HR,
2.72; CI 7.9–9.3; P = 0.11). Patients with bone invasionInternational Journal of Surgical Oncology 5
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Figure 3: The Kaplan Meier estimates of relapse-free survival. CRT:
chemoradiotherapy; RT: radiotherapy.
had poor relapse-free survival rates in both treated groups
(25%at3years),whereaspatientswithoutboneinvasionhad
improved outcomes (86% and 68% at 3 years for CRT and
RT, resp.) (Figure 4).
3.5. Patterns of Failure. Of the 6 patients who developed
recurrences after treatment with CRT, 2 patients developed
distant failures (dermal metastasis and lung, bones, adren-
als); both patients had advanced nodal disease at diagnosis
(Table 4). Four local or regional failures were observed in the
CRT-treated patients; three were isolated local failures and
one was both local and regional failure.
4. Discussion
Although NMSC is common worldwide, the prevalence of
the most aggressive forms of the disease is unknown, as
most cancer surveillance registries do not track NMSC. We
estimate that approximately 2–4% (or 6 patients/year) of all
head and neck tumors treated at our institution have a
diagnosis of NMSC over the years 2001 to 2007, making this
anuncommon,butnotrare,diseaseinourpractice.Current-
ly, no clear established role exists for chemotherapy in the
deﬁnitiveoradjuvanttreatmentofNMSCs,eitheraloneorin
combination with RT or surgery. This study is the ﬁrst report
on multiple patients with high-risk NMSCs of the head and
neck treated with concomitant RT and chemotherapy.
Our experience suggests that delivering chemotherapy
concomitantlywithRTisfeasibleandgenerallywelltolerated
with minimal morbidity as delivered in our patient pop-
ulation. Many of the chemotherapy regimens used in our
patients have a history of acceptable tolerability and success
for other cancers that employ CRT, most notably mucosal
head and neck cancer. Nearly all patients were able to
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Figure 4: Estimated relapse-free survival in patients with bone
invasion (a) and without bone invasion (b) treated with chemora-
diotherapy (CRT) and radiotherapy (RT).
complete the planned therapy: 87% of patients completed
at least 80% of the planned chemotherapy treatments and
93% completed the planned radiation treatments. This
compares favorably to previous experience of CRT using
similar chemotherapy regimens in other malignancies.
Skin toxicity was an important end-point to evaluate
because one of the primary goals in treating many of these
patients was to maximize the radiation dose to the skin sur-
f a c ei no r d e rt oe ﬀectively treat the tumor. This issue is
quite diﬀerent when irradiating mucosal carcinomas of the
head and neck (e.g., oropharynx, larynx) where minimizing
radiation dose to the skin is desired. The added skin toxicity
of combining chemotherapy in the setting of head and neck
NMSC, is therefore, not known.
Our data suggest that the use of concomitant chemother-
apy in the setting of non-skin-sparing radiation treatment
in the head and neck is feasible with acceptable skin toxicity
since radiation treatment breaks from excessive skin toxicity
wererare.Inourseries,therateofsevereradiationdermatitis
was only 13%, which is somewhat surprising since we
expected higher rates when tissue-equivalent bolus was used
in the majority (75%) of patients. It is likely that the
toxicity rates may have been underestimated due to the
retrospective nature of clinical record reviews. Clinicians
may have been reporting only acute skin toxicity outside the
target volume regions. In addition, clinicians may have had
diﬃculty in assessing in-ﬁeld radiation dermatitis in these
patients. Because the treated tumors frequently encompass
signiﬁcant portions of the radiation treatment ﬁelds, it may
havebeendiﬃculttodiﬀerentiatebetweenin-ﬁelddermatitis
and tumor necrosis.6 International Journal of Surgical Oncology
Table 3: Univariate and multivariate hazard ratios of relapse free survival.
Univariate Multivariate
Factor HR (95% CI) P value Factor HR (95% CI) P value
Basal cell histology 0.61 (0.3–1.3) 0.40 Bone invasion 9.43 (2.8–32) <0.01
Well-diﬀerentiated 0.93 (0.4–2.2) 0.93 Radiation alone 2.72 (7.9–9.3) 0.11
T4 disease 0.83 (0.4–1.7) 0.72 Nodal disease 2.60 (1.3–5.1) 0.01
Unresectable 0.84 0.76
Local invasion 2.25 (1.0–4.8) 0.17
Bone 5.25 (2.5–11.1) <0.01
Nerves 1.91 (0.9–4.1) 0.27
Soft tissue 1.21 (0.6–2.5) 0.73
Nodal disease 1.35 (0.8–2.2) 0.19
Positive margins 1.68 (0.8–3.5) 0.34
Recurrence 1.01 (0.5–2.1) 0.99
Radiation alone 0.71 (0.3–1.5) 0.53
Radiation break 2.04 (0.9–4.6) 0.27
Chemotherapy missed∗ 3.52 (1.4–8.8) 0.13
∗Applicable to chemoradiotherapy patients. HR, hazard ratio; CI, conﬁdence interval.
Table 4: Patterns of failure in chemoradiotherapy patients.
Patient primary site T stage N status Histology Adverse features Type of failure Time to relapse (months) Disease status
1N e c k T 4 N 0 B C C Aggressive local
invasion
Local 24 NED
2N o s e T 4 N 0 S C C
Gross perineural
invasion, positive
margins
Local 7 DOD
3 Cheek T4 N0 SCC Unresectable Local 6 DOD
4 Cheek T4 N1 SCC Unresectable, nodal
involvement
Local + regional 5 DOD
5 Scalp T3 N3 SCC Nodal involvement Distant 5 DOD
6 Ear T4 N2b SCC Unresectable, nodal
involvement
Distant 9 DOD
Abbreviations: BCC: basal cell carcinoma; SCC: squamous cell carcinoma; NED: no evidence of disease; DOD: died of disease.
Severe mucositis was rare (1 of 15 patients), which was
expectedinourpatientsbecausethemajorityoftheradiation
treatment volumes were focused on the skin or unilateral
necks, thus, minimizing dose to the oral cavity and pharynx.
Hematologic toxicity was also acceptable, primarily due to
the use of lower chemotherapy doses in a weekly schedule in
the majority of patients.
Due to the small numbers of patients in our study,
conclusions cannot be drawn regarding the eﬃcacy of this
treatment approach in head and neck NMSCs. And due to
the heterogeneity of patient characteristics between patients
treated with CRT and RT alone, the therapeutic gain of the
addition of chemotherapy to RT cannot be fully assessed in
this study. Locoregional control rates with CRT, however, are
encouraging, particularly given the high proportion of high-
risk features in this patient group as shown in Table 1.
Our results in both the CRT- and RT-treated patients
compare favorably with those reported in published liter-
ature. Institutional reviews of locally advanced T4 lesions
treated with RT alone consistently showed initial local con-
trol rates from 50% to 75% for primary lesions [3, 11, 12,14]
and 41% to 50% for recurrent lesions [3, 11]. Ultimate local
control rates after salvage therapy in these studies range from
59% to 90% [11, 14] but were frequently associated with
signiﬁcant morbidity. The locoregional control rate in our
study was 70% for patients with T4 lesions treated with
deﬁnitive CRT.
The main limitations of this study are the retrospective
nature and small numbers of patients. However, to our
knowledge, no other data other than case reports [26, 27]
exist on the use of CRT for NMSC of the head and neck.
Our experience provides initial data to support additional
exploration of this treatment approach for high-risk head
and neck NMSCs. Phase I and II studies combining RT with
chemotherapy or targeted agents are appropriate to consider
in these patients. Based on our institutional experience, a
weekly cisplatin or carboplatin regimen would be reasonable
to consider as concurrent chemotherapy platforms in future
clinical trials, given the acceptable toxicity and ease of
administration of these agents. The Trans-Tasman Radia-
tion Oncology Group (TROG 05.01) is currently enrolling
patients in a large phase III trial that randomizes resectedInternational Journal of Surgical Oncology 7
high-risk (node positive or T3-4) cutaneous squamous cell
carcinomas of the head and neck to adjuvant RT with or
without concomitant weekly carboplatin. Results from this
trial should provide important evidence on the beneﬁt or
lack of beneﬁt of adding chemotherapy to RT in these pa-
tients. Antiepidermal growth factor (EGFR) agents such as
cetuximab or erlotinib would be another approach to con-
sider as radiosensitizing agents, because preliminary reports
have suggested that the EGFR pathway may play an im-
portant role in the normal physiology of the cutaneous ep-
idermis, [15] and potentially in NMSC metastatic disease
[34, 35].
This study provides preliminary, hypothesis-generating
data on the feasibility and tolerability of combining chemo-
therapyconcomitantlywithRTforthetreatmentofhigh-risk
NMSCsoftheheadandneck.Ourdataalsoconﬁrmprevious
reports that some patients with NMSC are at high-risk of
death and recurrence for their disease. In the absence of
proven eﬃcacy, this type of multimodality treatment should
at least be considered as an alternative aggressive treatment
approach for locally advanced disease or tumors with nodal
metastasis. At our institution, we generally consider utilizing
concomitant CRT in patients that have unresectable disease
(which often include patients with bone invasion) or those
with positive margins or nodal disease after surgery. Before
becoming a widely accepted treatment approach in these
patients, further studies are needed to fully assess the toxicity
and better deﬁne subsets of patients that may beneﬁt from
combined modality treatment.
Disclosure
J. Tepper, was a consultant for Varian.
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